New research suggests that individuals who come off blockbuster slimming jabs like semaglutide or tirzepatide can put back on lost weight far faster than those who stop conventional diet and exercise plans.
Findings released in a leading medical journal shows that while overweight people frequently drop a large proportion of their total mass while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month once they quit.
"Users using these treatments must be aware of the potential of rapid weight regain when the treatment concludes," warns researcher Dr. Susan Jebb.
Such speed of recovery suggests a return to original mass within about one and a half years.
Analyzing Treatments
The analysis, which looked at 37 of studies involving over 9,000 of participants, compared the outcomes of the injectable medications with older methods.
Scientists point out that people who shed pounds through lifestyle changes alone usually see a less rapid weight regain—approximately 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Experts believe the way of the jabs is key to understanding the amplified regain.
The injections imitate a natural hormone called GLP-1, which controls hunger.
"Long-term administration of the hormone levels far above than normal could lead to the body to produce less of its endogenous hormone, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' leads to appetite is uncontrolled, making binge eating far more likely."
A Lifelong Condition?
Health authorities advise the injections for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Many experts contend that, considering the high risk of relapse, the treatment is often life-long.
This perspective is supported by pharmaceutical companies, who state that the findings "highlight the chronic character of obesity," akin to managing diseases like hypertension.
User Experiences
Users who have stopped the jabs explain a sudden return of hunger.
"It was like something activating and you're instantly extremely hungry," said one woman.
This difficulty is worsened if patients have not developed permanent dietary or behavioural modifications during treatment.
Growing Use
Survey data show that millions of adults in the UK have tried these injections in the last 12 months, with desire being substantial.
- Adoption is greater among women compared to males.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion access the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians stress that while GLP-1 drugs are potent agents for weight loss, they are not a standalone cure and maintained weight loss relies on combined behavioural management.
